A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

NCT02837991 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Development of CDX-014 discontinued

Conditions

Renal Cell Carcinoma (RCC)
Clear-cell Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Kidney Neoplasms
Metastatic Renal Cell Carcinoma
Ovarian Clear Cell Carcinoma

Interventions

DRUG: CDX-014

Sponsor

Celldex Therapeutics